Progressive Supranuclear Palsy - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：49頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Progressive Supranuclear Palsy - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Progressive Supranuclear Palsy - Pipeline Review, H1 2014’, provides an overview of the Progressive Supranuclear Palsy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Progressive Supranuclear Palsy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Progressive Supranuclear Palsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Progressive Supranuclear Palsy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Progressive Supranuclear Palsy - Pipeline Review, H1 2014’, provides an overview of the Progressive Supranuclear Palsy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Progressive Supranuclear Palsy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Progressive Supranuclear Palsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Progressive Supranuclear Palsy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Progressive Supranuclear Palsy Overview 6
Therapeutics Development 7
Pipeline Products for Progressive Supranuclear Palsy - Overview 7
Pipeline Products for Progressive Supranuclear Palsy - Comparative Analysis 8
Progressive Supranuclear Palsy - Therapeutics under Development by Companies 9
Progressive Supranuclear Palsy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Progressive Supranuclear Palsy - Products under Development by Companies 13
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 14
Summit Corporation plc 14
TauRx Therapeutics Ltd 15
Treventis Corporation 16
iPierian, Inc 17
Sellas Inc. 18
Progressive Supranuclear Palsy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
methylene blue - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ARC-100 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
zolpidem tartrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Seglin O-linked N-acetylglucosaminidase Inhibitors - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TRV-1387 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TRV-217 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
IPN-007 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibodies Targeting Tau Protein - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DP-C016 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Progressive Supranuclear Palsy - Recent Pipeline Updates 41
Progressive Supranuclear Palsy - Dormant Projects 45
Progressive Supranuclear Palsy - Product Development Milestones 46
Featured News & Press Releases 46
Dec 10, 2013: Potential Treatment for Parkinson’s & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
List of Tables
Number of Products under Development for Progressive Supranuclear Palsy, H1 2014 7
Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Progressive Supranuclear Palsy - Pipeline by Summit Corporation plc, H1 2014 14
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, H1 2014 15
Progressive Supranuclear Palsy - Pipeline by Treventis Corporation, H1 2014 16
Progressive Supranuclear Palsy - Pipeline by iPierian, Inc, H1 2014 17
Progressive Supranuclear Palsy - Pipeline by Sellas Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Progressive Supranuclear Palsy Therapeutics - Recent Pipeline Updates, H1 2014 41
Progressive Supranuclear Palsy - Dormant Projects, H1 2014 45
List of Figures
Number of Products under Development for Progressive Supranuclear Palsy, H1 2014 7
Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Progressive Supranuclear Palsy Overview 6
Therapeutics Development 7
Pipeline Products for Progressive Supranuclear Palsy - Overview 7
Pipeline Products for Progressive Supranuclear Palsy - Comparative Analysis 8
Progressive Supranuclear Palsy - Therapeutics under Development by Companies 9
Progressive Supranuclear Palsy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Progressive Supranuclear Palsy - Products under Development by Companies 13
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 14
Summit Corporation plc 14
TauRx Therapeutics Ltd 15
Treventis Corporation 16
iPierian, Inc 17
Sellas Inc. 18
Progressive Supranuclear Palsy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
methylene blue - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ARC-100 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
zolpidem tartrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Seglin O-linked N-acetylglucosaminidase Inhibitors - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TRV-1387 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TRV-217 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
IPN-007 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibodies Targeting Tau Protein - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DP-C016 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Progressive Supranuclear Palsy - Recent Pipeline Updates 41
Progressive Supranuclear Palsy - Dormant Projects 45
Progressive Supranuclear Palsy - Product Development Milestones 46
Featured News & Press Releases 46
Dec 10, 2013: Potential Treatment for Parkinson’s & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
List of Tables
Number of Products under Development for Progressive Supranuclear Palsy, H1 2014 7
Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Progressive Supranuclear Palsy - Pipeline by Summit Corporation plc, H1 2014 14
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, H1 2014 15
Progressive Supranuclear Palsy - Pipeline by Treventis Corporation, H1 2014 16
Progressive Supranuclear Palsy - Pipeline by iPierian, Inc, H1 2014 17
Progressive Supranuclear Palsy - Pipeline by Sellas Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Progressive Supranuclear Palsy Therapeutics - Recent Pipeline Updates, H1 2014 41
Progressive Supranuclear Palsy - Dormant Projects, H1 2014 45
List of Figures
Number of Products under Development for Progressive Supranuclear Palsy, H1 2014 7
Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29
